CiToxLAB Increases Inhalation Test Capabilities in North America and Europe
News Mar 09, 2012
CiToxLAB has announced that it has increased its inhalation test capabilities in North America and Europe.
The demand for studies to assess the safety of pharmaceuticals and chemicals via inhalation is increasing in Europe and North America with a relatively low number of facilities offering this service on both sides of the Atlantic.
CiToxLAB-North America has opened a new rodent and non-rodent inhalation facility following demand from clients, adding the ability to evaluate pharmaceuticals, biological compounds and inhalation devices.
For pharmaceutical companies inhalation tests are required for a range of drugs including those intended to treat allergy, asthma or COPD patients.
For chemical companies there is a need to test the consequences of inhaling chemical products, especially within the REACH (Registration, Evaluation and Authorization of Chemicals) program.
The studies conducted in CiToxLAB-North America will utilize seven rodent suites and five non-rodent suites and the facility is able to perform studies by the inhalation route in all species, including NHPs, enabling the CiToxLAB group to conduct work not currently performed in Europe.
In CiToxLAB-North America, the Canadian team is composed of staff with over 25 years’ cumulative experience in exposure of multiple animal species to single or repeated nose-only and oronasal exposure routes in liquids, powders, vapors and metered dose inhalers.
In Europe, CiToxLAB-Hungary is equipped with three rodent suites and one non-rodent suite and is currently doubling its rodent capacity in response to an increased demand, with the new area to be fully operational by the end of the second quarter 2012.
The site has run over 200 GLP inhalation studies in the last five years and has been conducting inhalation studies since 2000. The studies are conducted by a team of scientists and technicians with a combined 80 years’ experience.
The inhalation teams at CiToxLAB-Hungary and North America are supported by veterinary pathologists qualified to DVM level and experienced in inhalation studies, with board certified pathologists in North America.
Both sites have a full range of support services including analytical capabilities, and CiToxLAB-North America also has an on-site bioanalytical team working alongside the inhalation staff.
“We are now able to offer this type of inhalation testing on both sides of the Atlantic and at favourable prices when compared to our competitors,” said Jean-François Le Bigot, CEO of CiToxLAB.
Bigot continued, “In 2008 the inhalation department and senior management in Hungary were completely changed, with the addition of industry veterans with significant experience gained in the UK and North America. The services offered via the inhalation route in the Hungarian and North American facilities are complementary with the expertise provided by the other facilities, including CiToxLAB-France and CiToxLAB-Scantox in Denmark, which directly highlights the benefits of our acquisition of LAB Research last year.”
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE